A similar scenario is for the anti‐PD-L1 mAbs, with three approved PD-L1 inhibitors, that is, atezolizumab for urothelial carcinoma and non-small cell lung cancer [55, 56], avelumab for metastatic Merkel-cell carcinoma [57] and durvalumab for urothelial carcinoma and unresectable non-small cell lung cancer [58, 59]. This evidence concerns the gene CD274 and urothelial carcinoma.